BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen Y, Eng JS, Fajardo F, Liang L, Li C, Collins P, Tedesco D, Nolan-Stevaux O. Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway. J Immunother Cancer 2022;10:e004348. [PMID: 35296559 DOI: 10.1136/jitc-2021-004348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Long M, Mims AS, Li Z. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. Immunol Invest 2022;:1-39. [PMID: 36259611 DOI: 10.1080/08820139.2022.2131569] [Reference Citation Analysis]
2 Yang Z, Grande G, Hou Y, Wang C, Shi Y, Lerner RA, Wu P. Enhancing the anti-tumor efficacy of Bispecific T cell engagers via cell surface glycocalyx editing.. [DOI: 10.1101/2022.05.22.492978] [Reference Citation Analysis]
3 Sorrentino A, Menevse AN, Michels T, Volpin V, Durst FC, Sax J, Xydia M, Hussein A, Stamova S, Spoerl S, Heuschneider N, Muehlbauer J, Jeltsch KM, Rathinasamy A, Werner-Klein M, Breinig M, Mikietyn D, Kohler C, Poschke I, Purr S, Reidell O, Martins Freire C, Offringa R, Gebhard C, Spang R, Rehli M, Boutros M, Schmidl C, Khandelwal N, Beckhove P. Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation. J Immunother Cancer 2022;10:e004258. [PMID: 35606086 DOI: 10.1136/jitc-2021-004258] [Reference Citation Analysis]